CTIS2023-503258-11-00进行中（未招募）1 期
An Open-label, Single-dose Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Aticaprant (JNJ-67953964)
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 48
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
已完成
不适用
An open-label, single-dose study to evaluate the excretion and metabolism of oral [14C]-ONO-5788, and absolute bioavailability of oral ONO-5788 in healthy adult male subjectsacromegalyNL-OMON48245Ono Pharma UK Ltd.12
进行中（未招募）
1 期
A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy ParticipantsJPRN-jRCT2031200214Clinical, Medicine Creation Japan and Asia Clinical Development Department42
未知
1 期
An open-label, single-dose study to evaluate the pharmacokinetics and safety of DS-8500a in Japanese subjects with varying degrees of hepatic or renal functioSubjects with hepatic or renal impairmentJPRN-jRCT2080223081DAIICHI SANKYO CO., LTD.48
已完成
不适用
A clinical study of and Ayurveda Syrup named Amrita Bindu Syrup in treating patients with long term heart burn and sour belchCTRI/2019/01/017357Clinfound Clinical Research Services PvtLtd100
进行中（未招募）
1 期
Study to Evaluate the Safety and action of Etelcalcetide (AMG 416) in Paediatric Subjects Aged 2 to less than 18 Years with Secondary Hyperparathyroidism (sHPT) Receiving Maintenance HaemodialysisSecondary Hyperparathyroidism (sHPT) Receiving Maintenance HaemodialysisMedDRA version: 19.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2015-005051-28-BEAmgen Inc10